Former Chief Medical Officer · Actinium Pharmaceuticals, Inc. (ATNM)

Mark Berger

A named executive officer of Actinium Pharmaceuticals in every fiscal year CompBrief holds from FY2017 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$584,357

Salary $304,962Stock awards $0

FY2020: $829,958

3rd of 4 named executive officers at Actinium Pharmaceuticals by FY2021 total.

4 named officers on file for Actinium Pharmaceuticals, FY2021

Mark Berger’s pay file — $29

  • 5 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Actinium Pharmaceuticals’s whole pay program stands against its peers

  • Actinium Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ATNM→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed November 21, 2022 (DEF 14A).

Free

Get Mark Berger’s full pay file as a PDF — free

More than this page: up to 10 years of Mark’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Mark Berger compensation by year

Actinium Pharmaceuticals Summary Compensation Table · all 5 fiscal years held
In US dollars, as Actinium Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019FY2020FY2021
Salary$343,750$400,000$405,000$415,000$304,962
Bonus$0$75,000$85,000$100,000$0
Stock awards$0$0$0$0$0
Option awards$234,695$137,313$64,364$314,958$279,395
Non-equity incentive$0$0$0$0$0
Pension and deferred compensation$0$0$0$0$0
All other$0$0$0$0$0
Total$578,445$612,313$554,364$829,958$584,357

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Actinium Pharmaceuticals, Inc. DEF 14A filed November 21, 2022, accession 0001213900-22-074269, and prior-year filings.

How this page was built: the Actinium Pharmaceuticals, Inc. filed document, accession 0001213900-22-074269. Every figure is read from that document and cited to the page and table it appears in. Filed November 21, 2022.

$578K
$612K
$554K
$830K
$584K
FY17
FY18
FY19
FY20
FY21
SalaryBonusOption awards

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
Option8,800—$6.96
Option42,934—$9.55
Option217—$31.20
Option3,500—$23.49

Per the Outstanding Equity Awards at Fiscal Year-End table in Actinium Pharmaceuticals, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Actinium Pharmaceuticals’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Sandesh SethChairman and Chief Executive Officer (3)$2,335,323
Steve O’LoughlinChief Financial Officer$967,034
Mark Berger · this pageFormer Chief Medical Officer$584,357
Dale LudwigFormer Chief Scientific and Technology Officer$213,068

The full Actinium Pharmaceuticals compensation record

free company brief

This page is one person within Actinium Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Actinium Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Mark Berger's compensation dossier · One-time report. No refunds.